- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913444
Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO
Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Maintenance of adequate anticoagulation is of critical importance when patients are placed on extracorporeal life support, such as ECMO. During ECMO, a patient's entire blood volume is constantly exposed to the artificial surfaces of the ECMO circuit. This exposure activates the clotting cascade, and not only is the circuit at risk for clot formation, but the patient is also at risk for thromboembolic events. Hence anticoagulation is vital in allowing the ECMO circuit to support a patient's entire cardiopulmonary system for an extended period of time. Anticoagulation on ECMO is achieved primarily by the use of a heparin continuous infusion. Heparin's main mechanism of action is to bind to and activate an enzyme called antithrombin III (AT III). AT III is the principal inhibitor of the blood coagulation serine proteases - Thrombin and Factor Xa. In the presence of, and when bound to heparin, the inhibitory activity of AT III is greatly enhanced. AT III deficiency has been shown to be a common finding in pediatric patients requiring ECMO. Our center has reported that most neonatal patients requiring ECMO also have a significant degree of ATIII deficiency prior to, and during ECMO bypass. This deficiency may lead to challenges in achieving adequate anticoagulation while on ECMO. For this reason, our institution already supplements antithrombin during pre-ECMO circuit priming and for maintaining AT III levels above 70% during the entire length of ECMO support. Optimizing AT III levels may then improve anticoagulation while on ECMO. This study aims to determine the pharmacokinetics of recombinant antithrombin (ATryn®) supplementation. To date, the use of ATryn® has primarily been studied in adults. There is no published data to date, and no current studies on the pharmacokinetics of antithrombin III in neonates, and hence no published data on the pharmacokinetics of antithrombin III in the neonatal ECMO population. Since the use of antithrombin III in the neonatal ECMO patient population has not been thoroughly studied, the use of antithrombin III supplementation varies greatly among different neonatal intensive care units. Therefore, studies that aim at determining the pharmacokinetics of antithrombin III, particularly in ECMO patients, are important because of the lack of data and published studies in this patient population. By determining the pharmacokinetics of ATryn® in our neonatal ECMO patient population, we will aid in establishing standardized dosing and administration protocols for the supplementation of antithrombin in this specific patient population.
Summary of Risks and Benefits: ATryn® is FDA approved for use in the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin III deficient patients. ATryn® is a transgenically produced recombinant antithrombin concentrate from goat milk that is preservative free. It has an identical amino acid structure with minor glycosylation differences to endogenous human AT IIII. When assayed in the presence of excess heparin, the potency and efficacy of ATryn® is not different from that of plasma-derived AT III concentrates.5 ATryn® is administered as a continuous intravenous infusion, with weight-adjusted loading and maintenance dosing regimens as recommended by the medication's package insert. As dosing is specific to a patient's weight, this theoretically minimizes the risk for overdosing. In addition, as dosing is administered as a continuous infusion that is titrated to maintain stable AT III levels, there is the additional potential for less fluctuations in a patient's AT III levels. Not only will anticoagulation be optimized throughout the duration of ECMO support, but theoretically there may be a decreased need for, or less fluctuations in a patient's heparin requirements. This may furthermore minimize the risk for thromboembolic events within the ECMO circuit and the patient. Additionally, ATryn® is preservative free and because it is a recombinant product, it should be free from the risk of viral infection or prion transmission.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neonates requiring ECMO
- Must be < or = to 30 days of age
- Must be > or = to 37weeks corrected gestational age
Exclusion Criteria:
- Older than or = to 31 days of age
- Preterm neonates < 37weeks corrected gestational age
- Previously diagnosed hereditary coagulopathy or hemorrhagic disorder in the family
- Prior to recent anticoagulation use
- Known or suspected genetic or terminal disorder
- Known family history of hypersensitivity to goat's milk or goat milk products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Recombinant Antithrombin Infusion
The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO.
Loading dose(IU)=(100-baseline AT activity)/2.3
x Wt(kg).
Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2
x Wt(kg).
The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO.
This will be followed by the maintenance continuous infusion.
AT levels will be checked 2hours after the initiation of treatment.
For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment.
If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made.
Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antithrombin III Level
Time Frame: Every 6 hours until steady state within first 72 hours on ECMO
|
ATIII levels will be checked at a minimum of every 6 hours throughout a patient's ECMO course.
However, should dose adjustments be made to the ATryn infusion rate, ATIII levels will be checked 2hours after each dose adjustment.
Once the ATIII level is again within goal range, ATIII levels will resume to being checked every 6hours.
|
Every 6 hours until steady state within first 72 hours on ECMO
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philippe S Friedlich, MD, MS Epi, MBA, Children's Hospital Los Angeles
Publications and helpful links
General Publications
- Niebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs. 2011 Nov;35(11):1024-8. doi: 10.1111/j.1525-1594.2011.01384.x.
- Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J. 2006 Sep-Oct;52(5):513-6. doi: 10.1097/01.mat.0000242596.92625.a0.
- Sievert A, Uber W, Laws S, Cochran J. Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report. Perfusion. 2011 Jan;26(1):59-64. doi: 10.1177/0267659110385513. Epub 2010 Nov 5.
- Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003 Mar;43(3):390-4. doi: 10.1046/j.1537-2995.2003.00315.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCI-12-00147
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonates on ECMO
-
Assiut UniversityNot yet recruitingIron Study of Neonates: Factors Affecting and Impact on Their Health Status at Birth in Assuit University Children's Hospital
-
Southeast University, ChinaUnknown
-
Nanfang Hospital of Southern Medical UniversityDongguan People's Hospital; Foshan Hospital of Traditional Chinese Medicine; Shenzhen... and other collaboratorsRecruitingInflammatory Response | ECMOChina
-
Hamad Medical CorporationRecruitingMorality | VA-ECMOQatar
-
Rennes University HospitalTerminated
-
Beijing Anzhen HospitalRecruitingHigh-risk PCI | ECMOChina
-
Children's Hospital of Fudan UniversityChina Medical BoardRecruiting
-
Nantes University HospitalCompleted
-
Montefiore Medical CenterWithdrawn
Clinical Trials on Recombinant Antithrombin
-
rEVO BiologicsCompleted
-
Medical College of WisconsinChildren's National Research Institute; rEVO BiologicsTerminatedPostoperative HemorrhageUnited States
-
rEVO BiologicsCompletedAntithrombin III DeficiencyUnited States, France, United Kingdom, Germany, Canada, Austria, Australia, Italy
-
Mayo ClinicrEVO BiologicsTerminatedThrombophilia Due to Acquired Antithrombin III DeficiencyUnited States
-
rEVO BiologicsCompletedAntithrombin Deficiency, CongenitalFrance, United Kingdom, Germany, United States, Sweden, Italy
-
Seoul National University HospitalCompletedLiver Transplant; ComplicationsKorea, Republic of
-
Policlinico HospitalThe Mediterranean Institute for Transplantation and Advanced Specialized...Completed
-
Seoul National University HospitalActive, not recruitingHepatic Veno-Occlusive DiseaseKorea, Republic of
-
University of BariUnknownAortic Valve Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Acute Coronary Syndrome | Mitral Valve StenosisItaly
-
Kyowa Kirin Co., Ltd.Completed